Call Us : +603-9010-3058
Email Us : This email address is being protected from spambots. You need JavaScript enabled to view it.

You are here: Home Publications, News & Events News & Events

Monday11 December 2017

The Star : A newer approach to cancer treatment


HOSPITAL Universiti Kebangsaan Malaysia (HUKM) is currently carrying out a small trial utilising a form of immunotherapy called Human Initiated Therapeutic Vaccine (HITV).

In the trial, HITV is used in combination with modulated radiotherapy to treat advanced stage (metastatic) cancers.

HITV is pioneered by Hasumi International Research Foundation’s Dr Kenichiro Hasumi.

It involves the use of dendritic cells to stimulate an immune system response to cancer.

The dendritic cells are harvested from the patient and cultured in a laboratory.

Read more ...

东方网 : 遇见免疫曙光

oriental daily

隨著医疗科技日新月异,自体免疫治疗性疫苗(Human Initiated Therapeutic Vaccine,HITV)的研发,让面对著癌细胞復发或转移的病人,犹如在汪洋中抓到一块浮木,重燃起一线生存的希望。

於2005年研发的自体免疫治疗性疫苗(HITV),为晚期癌症病人带来了希望,尤其是患有弥漫型大B细胞淋巴瘤(Diffuse Large B Cells Lymphoma,DLBCL)却经歷常规治疗失效,正面对癌细胞復发或转移的病人。这类病人也称为復发性或顽固瀰漫性大型B细胞淋巴癌(Relapsed/Refractory Diffuse Large B Cells Lymphoma)病人。

由莲见贤一郎医生(Dr.Kenichiro Hasumi)研发的HITV疗法,主要机制是藉由特製的肿瘤抗原来教导人体免疫细胞辨识癌细胞,並辅以免疫调节剂来强化病人的免疫系统,以抵御顽强的癌细胞,並降低肿瘤復发或转移的发生。


Read more ...


HITV Lab is involved in cell-based biotechnology medical applications with special focus on Dendritic Cell-Based Immunotherapy for cancer. HITV Lab is committed to support an international collaboration in the FDA clinical trial of HITV Therapy in late-stage cancer patients led by the University of Maryland, USA.

FacebookTwitterGoogle Bookmarks